[go: up one dir, main page]

WO2018144093A3 - Formulations pour soins de la peau améliorés - Google Patents

Formulations pour soins de la peau améliorés Download PDF

Info

Publication number
WO2018144093A3
WO2018144093A3 PCT/US2017/059960 US2017059960W WO2018144093A3 WO 2018144093 A3 WO2018144093 A3 WO 2018144093A3 US 2017059960 W US2017059960 W US 2017059960W WO 2018144093 A3 WO2018144093 A3 WO 2018144093A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
collagen
formulations
skin care
improved skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/059960
Other languages
English (en)
Other versions
WO2018144093A2 (fr
Inventor
Mark A. Pinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2018144093A2 publication Critical patent/WO2018144093A2/fr
Publication of WO2018144093A3 publication Critical patent/WO2018144093A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des procédés d'administration de collagène et/ou d'acide hyaluronique à un sujet humain. Les vésicules lipidiques contenant du collagène et/ou de l'acide hyaluronique de l'invention fournissent un système d'administration de protéine de collagène et/ou d'acide hyaluronique qui améliore significativement l'état de la peau d'un sujet humain tout en éliminant les problèmes associés à l'instabilité chimique et physique du collagène et/ou de l'acide hyaluronique ainsi que des réponses immunitaires associées.
PCT/US2017/059960 2016-11-03 2017-11-03 Formulations pour soins de la peau améliorés Ceased WO2018144093A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416987P 2016-11-03 2016-11-03
US62/416,987 2016-11-03

Publications (2)

Publication Number Publication Date
WO2018144093A2 WO2018144093A2 (fr) 2018-08-09
WO2018144093A3 true WO2018144093A3 (fr) 2019-03-07

Family

ID=63040032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/059960 Ceased WO2018144093A2 (fr) 2016-11-03 2017-11-03 Formulations pour soins de la peau améliorés

Country Status (1)

Country Link
WO (1) WO2018144093A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
KR20210044191A (ko) 2018-06-04 2021-04-22 아큐티스, 인크. 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
WO2020205848A1 (fr) * 2019-04-01 2020-10-08 Geltor, Inc. Formulations topiques de collagènes recombinés
CN113993885B (zh) 2019-04-12 2025-04-25 格尔托公司 重组弹性蛋白及其生产
US20200405621A1 (en) * 2019-06-28 2020-12-31 The Procter & Gamble Company Skin Care Composition
US11786451B2 (en) 2019-06-28 2023-10-17 The Procter & Gamble Company Skin care composition
CN114761544A (zh) * 2019-07-26 2022-07-15 潘多姆科技私人有限公司 经生物工程化的调配物、其制备方法和实施方案
EP3973948A3 (fr) * 2019-07-29 2022-06-01 Giuliani S.p.A. Composition cosmétique avec remplisseur combiné et effet de régénération de la peau
MX2022003446A (es) 2019-09-23 2022-07-13 Dds Res Inc Composiciones de vesiculas lipidicas con agentes potenciadores de la penetracion.
CN111036156A (zh) * 2020-01-14 2020-04-21 江苏罗格斯生物科技有限公司 一种绿色功能因子精准控制材料的制备方法
CN111281840B (zh) * 2020-02-13 2022-03-29 广州伊尔美生物科技有限公司 一种亮颜美肤霜及其制备方法
US20230134782A1 (en) * 2020-05-07 2023-05-04 Arcutis Biotherapeutics, Inc. Treatment of skin conditions using high krafft temperature anionic surfactants
CN111494233B (zh) * 2020-06-02 2023-07-14 康珞生物科技（武汉）有限公司 一种胶原短肽脂质体的制备方法及应用
CN112057351B (zh) * 2020-09-22 2023-01-24 西安诗莱梦特生物科技有限公司 透明质酸-羟丙基甲基纤维素复合水凝胶及其制备方法和应用
CN116669696A (zh) * 2020-09-30 2023-08-29 格尔托公司 包含胶原或弹性蛋白多肽与活性成分的组合的组合物及其使用方法
WO2022072696A1 (fr) * 2020-09-30 2022-04-07 Geltor, Inc. Compositions comprenant des combinaisons de polypeptides de collagène ou d'élastine avec des principes actifs et leurs procédés d'utilisation
MX2023006602A (es) 2020-12-04 2023-08-07 Arcutis Biotherapeutics Inc Formulación tópica de roflumilast que tiene propiedades antimicoticas.
CN114246818A (zh) * 2021-03-08 2022-03-29 山东祥隆医药研究院有限公司 一种具有防敏、保湿、修复功效的精华乳及其制备方法
EP4313100A4 (fr) 2021-03-24 2025-10-15 Glo Pharma Inc Peptides et procédés de réduction de la pigmentation de la peau
BR112023019151A2 (pt) * 2021-03-24 2023-11-28 Glo Pharma Inc Vesículas lipídicas multissomais para distribuição de agentes cosméticos
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物
US20240216262A1 (en) * 2022-12-29 2024-07-04 Mary Kay Inc. Cosmetic compositions and methods of using same
CN116617146B (zh) * 2023-05-26 2024-12-17 广东巴松那生物科技有限公司 一种用于修复激素脸的护肤霜及其制备方法
CN117137840A (zh) * 2023-09-07 2023-12-01 河北纳科生物科技有限公司 一种重组胶原蛋白水油双相精华油及其制备方法
CN117017869B (zh) * 2023-09-15 2024-01-30 名宇(广东)化妆品科技有限公司 一种美白祛斑霜及制备方法
CN117982367A (zh) * 2024-01-25 2024-05-07 深圳摩尔雾化健康医疗科技有限公司 护肤活性物、护肤品
CN120661540A (zh) * 2025-08-19 2025-09-19 辽宁天贺生物科技研究院有限公司 基于寡聚透明质酸的医用创面护理组合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846561A (en) * 1991-02-14 1998-12-08 Baxter International Inc. Method of binding collagen recognizing substances to liposomes
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
US20100221319A1 (en) * 2005-10-03 2010-09-02 Pinsky Mark A Compositions and Methods for Improved Skin Care
KR20110036664A (ko) * 2009-10-02 2011-04-08 가부시키가이샤 페이스 콜라겐 수식 리포솜으로 이루어지는 화장료 기제 및 그것을 함유하는 피부 화장료
CN102988200A (zh) * 2012-12-10 2013-03-27 北京莱米瑞克科技发展有限公司 脂质体养颜护肤品

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846561A (en) * 1991-02-14 1998-12-08 Baxter International Inc. Method of binding collagen recognizing substances to liposomes
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
US20100221319A1 (en) * 2005-10-03 2010-09-02 Pinsky Mark A Compositions and Methods for Improved Skin Care
KR20110036664A (ko) * 2009-10-02 2011-04-08 가부시키가이샤 페이스 콜라겐 수식 리포솜으로 이루어지는 화장료 기제 및 그것을 함유하는 피부 화장료
CN102988200A (zh) * 2012-12-10 2013-03-27 北京莱米瑞克科技发展有限公司 脂质体养颜护肤品

Also Published As

Publication number Publication date
WO2018144093A2 (fr) 2018-08-09

Similar Documents

Publication Publication Date Title
WO2018144093A3 (fr) Formulations pour soins de la peau améliorés
WO2009086504A3 (fr) Formulations à base de collagène destinées à un soin cutané amélioré
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
CY1120264T1 (el) Υγρο σκευασμα για εισπνοη που περιεχει rpl554
SG10201909093XA (en) Mixed allergen compositions and methods for using the same
BR112013026706A2 (pt) composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico
CY1115991T1 (el) Φαρμακευτικη ψεκαζομενη συνθεση που περιλαμβανει ενα αναλογο της βιταμινης d προϊον και ενα κορτικοστεροειδες
GT200500254A (es) Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados.
CY1118934T1 (el) Παρασκευη ενεργης ακρως φωσφορυλιωμενης ανθρωπινης ν-ακετυλογαλακτοζαμινης-6-σουλφατασης και χρησεις αυτης
FR2944448B1 (fr) Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
UA106074C2 (uk) ПОХІДНІ 1H-ІМІДАЗО[4,5-c]ХІНОЛІНОНУ
MA43404A (fr) Compositions et procédés d'expression de multiples polypeptides biologiquement actifs à partir d'un seul vecteur pour le traitement d'affections et autres pathologies cardiaques
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA39342B2 (fr) Anticorps il -21
BR112021024632A2 (pt) Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea
CL2013003298A1 (es) Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo.
MA41150B1 (fr) Polymères de liaison aux protons pour administration orale
IN2014DN03213A (fr)
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.
Beijnen et al. Vaccine-induced CD8+ T cell responses in children: A review of age-specific molecular determinants contributing to antigen cross-presentation
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112015014095A2 (pt) entrega transmucosal de acetato de glatirâmero
HK1198137A1 (en) Disinfecting formulations and uses thereof
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17895323

Country of ref document: EP

Kind code of ref document: A2